昂利康：目前在研的创新药项目仅有一个

Core Insights - The company, Anglikon, has noted increased market attention on its innovative drug business, particularly regarding its ALK-N001 project, which is currently in Phase I clinical trials and received approval in April 2025 [1] - The company is also addressing investor interest in the ALK-N002 project, which is a new pipeline initiative planned for early 2025, with multiple candidate drugs currently under selection and discussion [1] Summary by Categories Innovative Drug Projects - The only ongoing innovative drug project is ALK-N001, which is in Phase I clinical trials as of the announcement date [1] - ALK-N002 is a new project planned for introduction in early 2025, with candidates still being evaluated [1] Regulatory and Disclosure - The company will adhere to strict information disclosure obligations based on the progress of its projects, particularly concerning the commercial secrets of candidate drug indications [1]